Active Biotech Concludes Agreement With Aventis Pasteur.Business Editors STOCKHOLM, Sweden--(BUSINESS WIRE)--Aug. 8, 2000 Active Biotech has started collaboration with Aventis Pasteur within the field of diarrhoea diseases. Aventis Pasteur will assume responsibility for the marketing, sales and distribution of Active Biotech's drinkable cholera vaccine, SBL SBL Society of Biblical Literature SBL Symbol Technologies, Inc. (NYSE symbol) SBL Spamhaus Block List SBL Space-Based Laser SBL Securities Borrowing and Lending SBL Supreme Beings of Leisure (band) Cholera Vaccine for all countries worldwide outside USA and Europe. The product has received a recommendation from the World Health Organisation (WHO), as the only vaccine on the market with a documented effect against cholera. Cholera is an acute intestinal infection with dramatic effects, occurring primarily in Africa, Asia and South America. The disease is caused by the Vibrio cholerae Vibrio chol·er·ae n. A bacterium that causes Asiatic cholera in humans; Koch's bacillus. Vibrio cholerae Infectious disease The Vibrio bacteria, which produces a toxin that causes severe diarrhoea and usually vomiting. This rapidly leads to dehydration and death if no treatment is given. Cholera is spread via contaminated water and food. In 1999, approx. 200,000 cases of cholera were reported to the WHO, but the real figures are thought to be considerably higher. The product included in the agreement also covers the indication against traveller's diarrhoea caused by the ETEC ETEC enterotoxigenic Escherichia coli. ETEC Enterotoxic Escherichia coli, see there bacteria (enterotoxigenic en·ter·o·tox·i·gen·ic adj. Of or being an organism containing or producing an enterotoxin. Enterotoxigenic E. coli E. coli: see Escherichia coli. E. coli in full Escherichia coli Species of bacterium that inhabits the stomach and intestines. E. coli can be transmitted by water, milk, food, or flies and other insects. ). The ETEC bacteria cause 30-40% of all cases of traveller's diarrhoea. Active Biotech is currently successfully marketing the product with this ETEC indication under the trademark Dukoral in Sweden and Norway. According to the agreement, Aventis Pasteur will apply for registration also for Dukoral against traveller's diarrhoea on various international markets. Active Biotech will continue to sell the product for both indications in the Nordic countries through its own sales organisation. The estimated turnover this year in Sweden and Norway is approx. 45 Million SEK SEK In currencies, this is the abbreviation for the Swedish Krona. Notes: The currency market, also known as the Foreign Exchange market, is the largest financial market in the world, with a daily average volume of over US $1 trillion. ( 5,3 Million Euros); a 100% increase compared with 1999. The total turnover, including export, is estimated to reach 80 Million SEK (9,5 Million Euros), for year 2000. The agreement with Aventis Pasteur specifies that Active Biotech will produce the SBL Cholera Vaccine and Dukoral. Production will take place at Active Biotech's units in Stockholm and Matfors. Scaling up of the capacity is being made during 1999-2000. Active Biotech holds a prominent position within the area of diarrhoea illnesses. Studies in this field began as early as in the 1970s in co-operation with Professors Ann-Mari Svennerholm and Jan Holmgren at Goteborg University. This research gave rise to the SBL Cholera Vaccine against cholera and the Dukoral travel vaccine against traveller's diarrhoea caused by ETEC infection. A dry formulation in powder form is being developed to facilitate transport and access to SBL Cholera Vaccine in the developing countries. "The agreement is important for Active Biotech's vaccine activities. The company gains access to Aventis Pasteur's extensive expertise in international registration, development and marketing of vaccines. At the same time, Active Biotech can fully utilise its production units," says Sven Andreasson, President & CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of Active Biotech. Aventis Pasteur, a world leader in vaccines with the broadest range of products, produces more than one billion doses of vaccines every year to immunize im·mu·nize v. 1. To render immune. 2. To produce immunity in, as by inoculation. im 400 million people around the world. Aventis Pasteur, headquartered in Lyon, France, is one of the pharmaceutical activities of Aventis SA. Aventis Pasteur operated under the Pasteur Merieux Connaught name until the creation of Aventis. Aventis S.A. (NYSE NYSE See: New York Stock Exchange : AVE) is a world leader in life sciences. Focused on two core business areas - pharmaceuticals and agriculture - Aventis is dedicated to improving life through the discovery and development of innovative products in the fields of prescription drugs, vaccines, therapeutic proteins, crop production and protection, animal health and nutrition. With global corporate headquarters in Strasbourg, France, Aventis employs around 95,000 people in more than 120 countries and recorded pro forma As a matter of form or for the sake of form. Used to describe accounting, financial, and other statements or conclusions based upon assumed or anticipated facts. The phrase pro forma sales in 1999 of 20.5 billion euros ($20.7 billion). Aventis was launched in December 1999 through the merger of Hoechst AG of Germany and Rhone-Poulenc S.A of France. Active Biotech AB is a biotechnology company focusing on research and development of pharmaceuticals and vaccines. Our expertise lies in the knowledge of the human immune defence system. We have a high-quality project portfolio and extensive financial resources. The main products are the Dukoral travel vaccine, the SBL Cholera Vaccine, the vaccine against traveller's diarrhoea (ETEC), medicine for multiple sclerosis (SAIK SAIK Sandvikens Aik ) and cancer (TTS (1) See text-to-speech. (2) (Transaction Tracking System) Software that monitors a transaction until completion. In the event of a hardware or software failure, it ensures that the database is brought back to its former state before the attempt to ). Active Biotech's turnover was MSEK MSEK Meyer, Suozzi, English & Klein (New York law firm) MSEK Million Swedish Kroner 267 in 1999. ----------------------------- This information was brought to you by BIT http://www.bit.se The following files are available for download: http://www.bit.se/bitonline/2000/08/08/20000808BIT00130/bit0001.doc http://www.bit.se/bitonline/2000/08/08/20000808BIT00130/bit0002.pdf |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion